Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Mink Therapeutics Inc INKT

Healthcare Biotechnology
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical... see more

Current News (NDAQ:INKT)

MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers

GlobeNewswire 5 days ago

MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia

GlobeNewswire February 3, 2026

MiNK Therapeutics and University of Wisconsin-Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease

GlobeNewswire January 8, 2026

MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors

GlobeNewswire November 20, 2025

MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation

GlobeNewswire November 14, 2025

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1-Refractory Solid Tumors at SITC 2025

GlobeNewswire November 7, 2025

MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development

GlobeNewswire November 5, 2025

MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

GlobeNewswire October 30, 2025

MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors

GlobeNewswire September 29, 2025
View More News ››

Opinion & Analysis (NDAQ:INKT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:INKT)

Need another financing

3M at 10.00 ? Will need a lot more in the future. IMO
Form001 - November 19, 2025

Difficult to understand the 76.00 in july

For now, no volume.....
Form001 - November 18, 2025

52 week low, 4,56

No volume.........can retest the low. IMO
Form001 - November 17, 2025

Going to 12.00

IMO
Form001 - September 4, 2025

Looks that nobody believe in Mink

IMO
Form001 - August 28, 2025

Retest 12.00

With no volume, it's a possibility. IMO
Form001 - August 26, 2025
View more Bullboard ››

US Energy Corp

US Energy Corp

U.S. Energy Corp., an independent energy company, focuses on the acquisition, exploration, and development of industrial gas, ...
View More »

Podcasts